low affinity gpcrs for metabolic intermediates: challenges for pharmacologists

Clicks: 251
ID: 256837
2012
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #161 of 262 articles by views in aip advances

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 262 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
The discovery that a number of metabolic intermediates can act through G protein-coupled receptors has attracted great interest in the field and has led to new therapeutic targets for a variety of diseases such as hypertension, type 2 diabetes, inflammatory disorders and metabolic syndrome. However, the low apparent affinity of these ligands for their cognate receptors poses a number of challenges for pharmacologists interested in investigating structure, function or physiology at these receptors. Furthermore, in each case, the endogenous ligands matched to their receptors have other, well established metabolic roles and thus selectivity is difficult to achieve. This review will discuss some of the issues researchers face when working with these receptors and highlight the ways in which a number of these obstacles have been overcome.
Reference Key
smith2012frontierslow Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Nicola J Smith;Nicola J Smith
Journal aip advances
Year 2012
DOI
10.3389/fendo.2012.00001
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.